Nuveen LLC Takes $643,000 Position in Cerus Corporation $CERS

Key Points

• Nuveen LLC has acquired a new stake in Cerus Corporation worth approximately $643,000, owning around 0.24% of the company as of its recent SEC filing.
• Cerus reported a loss of $0.03 EPS for its last quarter, missing expectations, but exceeded revenue forecasts with $60.10 million in revenue.
• The stock price of Cerus increased by 3.1%, and as of Thursday, it was trading at $1.31 with a market cap of $251.13 million.

Nuveen LLC purchased a new stake in Cerus Corporation (NASDAQ:CERS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 462,550 shares of the biotechnology company's stock, valued at approximately $643,000. Nuveen LLC owned 0.24% of Cerus at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CERS. Millennium Management LLC increased its stake in Cerus by 52.1% in the fourth quarter. Millennium Management LLC now owns 2,877,932 shares of the biotechnology company's stock valued at $4,432,000 after acquiring an additional 986,286 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Cerus by 6.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock worth $2,466,000 after purchasing an additional 107,771 shares in the last quarter. Northern Trust Corp raised its stake in shares of Cerus by 1.2% during the fourth quarter. Northern Trust Corp now owns 1,634,780 shares of the biotechnology company's stock valued at $2,518,000 after acquiring an additional 18,878 shares during the last quarter. Two Sigma Investments LP grew its holdings in Cerus by 121.6% in the fourth quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company's stock worth $917,000 after purchasing an additional 326,605 shares during the period. Finally, Lazard Asset Management LLC boosted its holdings in Cerus by 40.6% during the fourth quarter. Lazard Asset Management LLC now owns 536,789 shares of the biotechnology company's stock worth $826,000 after purchasing an additional 155,038 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company's stock.

Cerus Trading Down 1.9%

Shares of Cerus stock traded down $0.03 during trading on Monday, reaching $1.31. The company's stock had a trading volume of 297,082 shares, compared to its average volume of 1,298,470. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The firm's 50-day moving average is $1.34 and its two-hundred day moving average is $1.37. The company has a market cap of $250.17 million, a price-to-earnings ratio of -13.05 and a beta of 1.63. Cerus Corporation has a 52-week low of $1.12 and a 52-week high of $2.24.

Cerus (NASDAQ:CERS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. The company had revenue of $60.10 million for the quarter, compared to analysts' expectations of $51.80 million. Cerus has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Cerus Corporation will post -0.08 earnings per share for the current year.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.